Lorenzo Braghieri
Research Subjects
Research Interests
Lorenzo Braghieri has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
Koji Takeda
Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio
4 shared publicationsMelana Yuzefpolskaya
Department of Medicine, Division of Cardiology, Columbia University Irving Medical Center, New York, New York
4 shared publicationsNir Uriel
Department of Medicine, Division of Cardiology, Columbia University Irving Medical Center, New York, New York
4 shared publicationsAlberto Pinsino
Department of Medicine, Division of Cardiology, Columbia University Irving Medical Center, New York, New York
3 shared publications- Giulio M. Mondellini
Department of Cardiology, Cardiovascular Institute, Thoraxcenter (G.M.M., A.J.M.E., C.L.M., N.M.V.M.), Erasmus University Medical Center, Rotterdam, the Netherlands
3 shared publications Osamah Z. Badwan
Department of Internal Medicine, Cleveland Clinic, Cleveland, OH
3 shared publications
Latest Publications
- Open Access
- 21 October 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (20) , e040631
Impact of Obstructive Sleep Apnea on Arrhythmia and Quality‐of‐Life Outcomes After Catheter Ablation of Atrial Fibrillation
Background: Catheter ablation is a first‐line therapy for atrial fibrillation (AF). We evaluated the impact of obstructive sleep apnea (OSA) on arrhythmia and postablation quality‐of‐life outcomes among AF subtypes. Methods: Consecutive patients undergoing AF ablation (2013–2022) at a tertiary center were enrolled and assessed for arrhythmia recurrence over 3‐year follow‐up. A subset of patients enrolled in an automated patient‐reported outcomes platform were assessed for quality of life, including Atrial Fibrillation Severity Score and AF burden (AF duration and frequency scores). Results: A total of 7020 patients were included: 3380 with paroxysmal AF (PAF) and 3640 with persistent AF (PersAF), of whom 729 and 943 had OSA, respectively (PAF: age, 66.5±10 years [69% men]; PersAF: age, 66.1±9 years [76% men]). Unlike patients with PersAF, those with PAF and OSA had higher AF recurrence (PAF: no OSA=70% versus OSA=64% [ P P =0.24]). Baseline OSA was independently associated with a 30% increased AF recurrence risk (hazard ratio, 1.30; P P <0.001 for all comparisons): (1) median AF symptom severity (PAF: no OSA 10→2, OSA 12→4; PersAF: 12→4 in both groups); and (2) median AF duration (PAF: 6.25→0 in both groups; PersAF: 10→0 in both groups); median AF frequency (PAF: 6→0 in both groups; PersAF: 9→0 in both groups). Conclusions: Baseline OSA was associated with an increased AF recurrence risk in patients with PAF, but not in those with PersAF. Catheter ablation resulted in improvement of quality‐of‐life metrics irrespective of baseline OSA among AF subtypes.
- 21 October 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (20) , e040631
Open AccessImpact of Obstructive Sleep Apnea on Arrhythmia and Quality‐of‐Life Outcomes After Catheter Ablation of Atrial Fibrillation
Background: Catheter ablation is a first‐line therapy for atrial fibrillation (AF). We evaluated the impact of obstructive sleep apnea (OSA) on arrhythmia and postablation quality‐of‐life outcomes among AF subtypes. Methods: Consecutive patients undergoing AF ablation (2013–2022) at a tertiary center were enrolled and assessed for arrhythmia recurrence over 3‐year follow‐up. A subset of patients enrolled in an automated patient‐reported outcomes platform were assessed for quality of life, including Atrial Fibrillation Severity Score and AF burden (AF duration and frequency scores). Results: A total of 7020 patients were included: 3380 with paroxysmal AF (PAF) and 3640 with persistent AF (PersAF), of whom 729 and 943 had OSA, respectively (PAF: age, 66.5±10 years [69% men]; PersAF: age, 66.1±9 years [76% men]). Unlike patients with PersAF, those with PAF and OSA had higher AF recurrence (PAF: no OSA=70% versus OSA=64% [ P P =0.24]). Baseline OSA was independently associated with a 30% increased AF recurrence risk (hazard ratio, 1.30; P P <0.001 for all comparisons): (1) median AF symptom severity (PAF: no OSA 10→2, OSA 12→4; PersAF: 12→4 in both groups); and (2) median AF duration (PAF: 6.25→0 in both groups; PersAF: 10→0 in both groups); median AF frequency (PAF: 6→0 in both groups; PersAF: 9→0 in both groups). Conclusions: Baseline OSA was associated with an increased AF recurrence risk in patients with PAF, but not in those with PersAF. Catheter ablation resulted in improvement of quality‐of‐life metrics irrespective of baseline OSA among AF subtypes.
- 12 June 2024
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 17 (10) , 1133-1145
Longitudinal Assessment of Left Atrial Remodeling in Patients With Chronic Severe Aortic Regurgitation
- 12 June 2024
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 17 (10) , 1133-1145
Longitudinal Assessment of Left Atrial Remodeling in Patients With Chronic Severe Aortic Regurgitation
- 11 January 2024
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 70 (5) , 456-459
The Impact of the 2018 Allocation System Change on Patients Bridged With Durable Left Ventricular Assist Device: An Updated UNOS Registry Analysis
- 11 January 2024
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 70 (5) , 456-459
The Impact of the 2018 Allocation System Change on Patients Bridged With Durable Left Ventricular Assist Device: An Updated UNOS Registry Analysis
- 29 December 2023
- Published by Elsevier in The American Journal of Cardiology
- Vol. 225, 22-24
Quality of Life Outcomes of Atrial Fibrillation Ablation in Heart Failure With Preserved or Mildly Reduced Left Ventricular Systolic Function
- 29 December 2023
- Published by Elsevier in The American Journal of Cardiology
- Vol. 225, 22-24
Quality of Life Outcomes of Atrial Fibrillation Ablation in Heart Failure With Preserved or Mildly Reduced Left Ventricular Systolic Function
- Open Access
- 11 November 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (22) , 7042
Endocarditis after Transcatheter Aortic Valve Replacement
Transcatheter aortic valve replacement (TAVR) use is gaining momentum as the mainstay for the treatment of aortic stenosis compared to surgical aortic valve replacement (SAVR). Unfortunately, TAVR-related infective endocarditis (TAVR-IE) is expected to be detected more and more as a result of the ever-expanding indications in younger patients. Given the overall poor prognosis of TAVR-IE, it is imperative that clinicians familiarize themselves with common presentations, major risk factors, diagnostic pitfalls, therapeutic approaches, and the prevention of TAVR-IE. Herein, we review all of the above in detail with the most updated available literature.
- 11 November 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (22) , 7042
Open AccessEndocarditis after Transcatheter Aortic Valve Replacement
Transcatheter aortic valve replacement (TAVR) use is gaining momentum as the mainstay for the treatment of aortic stenosis compared to surgical aortic valve replacement (SAVR). Unfortunately, TAVR-related infective endocarditis (TAVR-IE) is expected to be detected more and more as a result of the ever-expanding indications in younger patients. Given the overall poor prognosis of TAVR-IE, it is imperative that clinicians familiarize themselves with common presentations, major risk factors, diagnostic pitfalls, therapeutic approaches, and the prevention of TAVR-IE. Herein, we review all of the above in detail with the most updated available literature.
- Open Access
- 2 October 2023
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
- Vol. 90 (10) , 625-631
What is the most appropriate management of patients with acute decompensated heart failure who develop in-hospital hypotension?
What is the most appropriate management of patients with acute decompensated heart failure who develop in-hospital hypotension? Q: Because the majority of patients with acute decompensated heart failure remain at high risk for in-hospital hypotension owing to low cardiac output and neurohormonal blockade from guideline-directed medical therapy, 1 we recommend a tailored approach to risk-stratify patients with acute decompensated heart failure that focuses on avoidance, early recognition, and management of symptomatic and clinically signifi cant hypotension.
- 2 October 2023
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
- Vol. 90 (10) , 625-631
Open AccessWhat is the most appropriate management of patients with acute decompensated heart failure who develop in-hospital hypotension?
What is the most appropriate management of patients with acute decompensated heart failure who develop in-hospital hypotension? Q: Because the majority of patients with acute decompensated heart failure remain at high risk for in-hospital hypotension owing to low cardiac output and neurohormonal blockade from guideline-directed medical therapy, 1 we recommend a tailored approach to risk-stratify patients with acute decompensated heart failure that focuses on avoidance, early recognition, and management of symptomatic and clinically signifi cant hypotension.
- 1 September 2023
- Published by Elsevier in The American Journal of Cardiology
- Vol. 205, 422-424
Dual Antiplatelet Therapy Duration After Percutaneous Coronary Interventions of Left Main Coronary Artery Disease: A Meta-Analysis
- 1 September 2023
- Published by Elsevier in The American Journal of Cardiology
- Vol. 205, 422-424
Dual Antiplatelet Therapy Duration After Percutaneous Coronary Interventions of Left Main Coronary Artery Disease: A Meta-Analysis
- 1 August 2023
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
- Vol. 90 (8) , 483-489
Evaluating troponin elevation in patients with chronic kidney disease and suspected acute coronary syndrome
Many patients with chronic kidney disease have chronically elevated cardiac troponin levels, and if they present with symptoms suggesting an acute coronary syndrome, it is often difficult to determine if this is the correct diagnosis. This article briefly reviews the major challenges in diagnosing acute coronary syndrome in patients with chronic kidney disease, describes the mechanisms and prognostic significance of troponin elevation in chronic kidney disease, and provides a diagnostic algorithm to risk-stratify patients with chronic kidney disease who have troponin elevation and suspected acute coronary syndrome.
- 1 August 2023
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
- Vol. 90 (8) , 483-489
Evaluating troponin elevation in patients with chronic kidney disease and suspected acute coronary syndrome
Many patients with chronic kidney disease have chronically elevated cardiac troponin levels, and if they present with symptoms suggesting an acute coronary syndrome, it is often difficult to determine if this is the correct diagnosis. This article briefly reviews the major challenges in diagnosing acute coronary syndrome in patients with chronic kidney disease, describes the mechanisms and prognostic significance of troponin elevation in chronic kidney disease, and provides a diagnostic algorithm to risk-stratify patients with chronic kidney disease who have troponin elevation and suspected acute coronary syndrome.
- 23 April 2023
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 42 (9) , 1223-1232
Pulsatility and flow patterns across macro- and microcirculatory arteries of continuous-flow left ventricular assist device patients
- 23 April 2023
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 42 (9) , 1223-1232
Pulsatility and flow patterns across macro- and microcirculatory arteries of continuous-flow left ventricular assist device patients
- 18 August 2022
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 42 (9) , 697-706
Temporal shifts in safety and efficacy profile of mycophenolate mofetil 2 g versus 3 g daily early after heart transplantation
Study Objective: Mycophenolate mofetil (MMF) is the gold‐standard immunosuppressive agent in heart transplantation (HT), but dose‐dependent toxicities (e.g., neutropenia) are frequent. Gut bacteria β‐d‐glucuronidases (GUS) modulate MMF bioavailability, and changes in the intestinal flora may influence the pharmacokinetics of MMF. The objective of this study was to evaluate the safety and efficacy of MMF 1.5 g every 12 h (q12) [high‐dose, HD] versus 1 g q12 [low‐dose, LD] and explore the association between neutropenia and GUS.Measurements: We compared the incidence of acute cellular rejection (ACR) and neutropenia during the first 6 months post‐HT. The association between neutropenia and GUS was investigated in an exploratory analysis on a subset of patients with prospectively collected stool data. Stool samples were analyzed using 16S rRNA sequencing.Main Results: A total of 168 patients (120 MMF‐HD, 48 MMF‐LD; mean age 55.7 years, 79% male) were studied. Neutropenia occurred in 38.6% of patients at a median of 106 [64–143] days. Freedom from neutropenia was lower in MMF‐HD compared with MMF‐LD (57% vs. 73%, p = 0.03). ACR (≥1R/1B) occurred in 37.5% of patients at a median of 20 [10–96] days, while high‐grade ACR (≥2R/3A) occurred in 11.3% at a median of 14 [9–89] days. Freedom from ACR was similar between groups. MMF‐LD was associated with more high‐grade ACR (hazard ratio [HR] 3.47, 95% confidence interval [CI] 1.09–11.08, p = 0.03) during the first month, but less neutropenia (HR 0.54, 95% CI 0.29–1.00, p = 0.05) between 1 and 6 months. GUS‐producing bacteria were more abundant in neutropenic patients.Conclusions: MMF‐LD was associated with higher rates of early high‐grade ACR and lower rates of later neutropenia. Further studies are warranted to test whether temporal MMF dose adjustments and gut microbial composition could improve clinical outcomes post‐HT.
- 18 August 2022
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 42 (9) , 697-706
Temporal shifts in safety and efficacy profile of mycophenolate mofetil 2 g versus 3 g daily early after heart transplantation
Study Objective: Mycophenolate mofetil (MMF) is the gold‐standard immunosuppressive agent in heart transplantation (HT), but dose‐dependent toxicities (e.g., neutropenia) are frequent. Gut bacteria β‐d‐glucuronidases (GUS) modulate MMF bioavailability, and changes in the intestinal flora may influence the pharmacokinetics of MMF. The objective of this study was to evaluate the safety and efficacy of MMF 1.5 g every 12 h (q12) [high‐dose, HD] versus 1 g q12 [low‐dose, LD] and explore the association between neutropenia and GUS.Measurements: We compared the incidence of acute cellular rejection (ACR) and neutropenia during the first 6 months post‐HT. The association between neutropenia and GUS was investigated in an exploratory analysis on a subset of patients with prospectively collected stool data. Stool samples were analyzed using 16S rRNA sequencing.Main Results: A total of 168 patients (120 MMF‐HD, 48 MMF‐LD; mean age 55.7 years, 79% male) were studied. Neutropenia occurred in 38.6% of patients at a median of 106 [64–143] days. Freedom from neutropenia was lower in MMF‐HD compared with MMF‐LD (57% vs. 73%, p = 0.03). ACR (≥1R/1B) occurred in 37.5% of patients at a median of 20 [10–96] days, while high‐grade ACR (≥2R/3A) occurred in 11.3% at a median of 14 [9–89] days. Freedom from ACR was similar between groups. MMF‐LD was associated with more high‐grade ACR (hazard ratio [HR] 3.47, 95% confidence interval [CI] 1.09–11.08, p = 0.03) during the first month, but less neutropenia (HR 0.54, 95% CI 0.29–1.00, p = 0.05) between 1 and 6 months. GUS‐producing bacteria were more abundant in neutropenic patients.Conclusions: MMF‐LD was associated with higher rates of early high‐grade ACR and lower rates of later neutropenia. Further studies are warranted to test whether temporal MMF dose adjustments and gut microbial composition could improve clinical outcomes post‐HT.